Aller au contenu principal
2026 conference-abstract

Abstract 5843: Beyond viability: Post treatment single cell and spatial transcriptomic profiling in mixtures of PRISM barcoded cancer cell lines

0Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : us. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Abstract PRISM is a highly multiplexed, genomic barcode-based cell line viability technology of nearly 1000 solid tumor and hematopoietic cell lines. The unique cell line barcodes enable the cell lines to be multiplexed into pools of dozens to hundreds of different cell lines per well or dish, which greatly reduces the time and costs required to profile the viability effects of compounds or biologics across 900+ cell lines. Leveraging underlying genomic characterization of these cell lines enables the discovery of biomarkers of sensitivity and resistance. In addition to enabling viability screening in 900+ cell lines at scale, the PRISM barcoding technology also enables us to profile post-perturbation RNA transcript and protein changes in mixtures of cell lines by adapting commercially available single cell sequencing (10x Genomics Flex v2) and spatial transcriptomic assays (Element Biosciences AVITI24). Expanding the phenotypic readout capabilities of the PRISM technology beyond viability to include gene and protein changes will provide deeper insight into drug mechanisms of action, resistance, off-target effects, and heterogeneity of response. Here we present our work developing multiomic phenotypic profiling assays in barcoded PRISM cell line pools. We leverage 10x Genomics Flex v2 (for genomewide RNA single cell sequencing and PRISM barcode identification) in conjunction with the Flex-compatible Proteintech Human Discovery antibody panel (to measure abundances of 300+ proteins) in response to perturbations. In a pilot of 100 cell lines spanning 20+ lineages, we reliably detect 99 cell lines, recovering on average ∼7000 unique genes per cell. In parallel, we are exploring the potential of Element Biosciences AVITI24 for spatial transcriptomic readouts in pools of PRISM cell lines. In a pilot of 25 cell lines spanning 15 lineages, we detect each of the 25 cell lines and although we recover fewer counts per cell, we recover morphology features from 6 cell paint stains (membrane, nucleus, actin, mitochondria, golgi, and ER). In both assays, we treated with a pan-RAS inhibitor and observed a concordant gene signature in differentially expressed genes. The 10x Flex v2 assay has the benefit of depth (detecting more transcripts per cell), while the Element imaging workflow enables culturing cells directly on the flowcell and provides spatial and morphological features. Thus, the two assays are highly complementary. We identify commonalities as well as distinct insights obtained by the two technological approaches and identify cell line specific responses. Citation Format: Laura Doherty, Ashish B. George, Mustafa Kocak, Paul Lund, Andrew Kohlway, Andrew Boddicker, Ben Song, Carlos Ruiz Perez, Bryan Lajoie, Catarina D. Campbell, Matthew G. Rees, Jennifer A. Roth. Beyond viability: Post treatment single cell and spatial transcriptomic profiling in mixtures of PRISM barcoded cancer cell lines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 5843.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Abstract 5843: Beyond viability: Post treatment single cell and spatial transcriptomic profiling in mixtures of PRISM barcoded cancer cell lines
Date Crossref
03/04/2026
Éditeur
American Association for Cancer Research (AACR)
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Où se fait cette recherche

  • Broad Institute pays non établi dans la notice
    Organisation à but non lucratif
  • 10X Genomics (United States) pays non établi dans la notice
    Entreprise
  • Electronic BioSciences (United States) pays non établi dans la notice
    Entreprise
  • Cambridge pays non établi dans la notice
    Institution
  • Pleasanton pays non établi dans la notice
    Institution
  • San Diego pays non établi dans la notice
    Institution

Broad Institute, 10X Genomics (United States) et Electronic BioSciences (United States), avec 3 autres affiliations.

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Single-cell and spatial transcriptomicsCancer Genomics and DiagnosticsCell Image Analysis Techniques

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.